Trial Profile
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of Xyrem with an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects with Narcolepsy with Cataplexy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 25 Nov 2020
Price :
$35
*
At a glance
- Drugs Sodium oxybate (Primary)
- Indications Cataplexy; Narcolepsy
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms EXPRESS
- Sponsors Jazz Pharmaceuticals Inc
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 26 Apr 2019 Status changed from active, no longer recruiting to completed.